Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
MD Anderson and Cyclacel announce strategic alliance to evaluate novel drugs for hematological malignancies

MD Anderson and Cyclacel announce strategic alliance to evaluate novel drugs for hematological malignancies

Could 'natural adaptive therapies' be a better way to keep cancer under control?

Could 'natural adaptive therapies' be a better way to keep cancer under control?

New way of using natural killer cells makes immunotherapy viable to more patients

New way of using natural killer cells makes immunotherapy viable to more patients

Study sheds light on transport of enzyme involved in stem cell differentiation to DNA

Study sheds light on transport of enzyme involved in stem cell differentiation to DNA

Researchers caution that expediting HLH treatment may miss underlying cancers

Researchers caution that expediting HLH treatment may miss underlying cancers

Why patients with ALL relapse after CAR-T cell therapy

Why patients with ALL relapse after CAR-T cell therapy

Why patients with ALL relapse after CAR-T cell therapy

Why patients with ALL relapse after CAR-T cell therapy

New analysis confirms value of minimal residual disease as prognostic indicator in multiple myeloma

New analysis confirms value of minimal residual disease as prognostic indicator in multiple myeloma

FDA permits marketing of ClonoSEQ assay to detect minimal residual disease in blood cancer patients

FDA permits marketing of ClonoSEQ assay to detect minimal residual disease in blood cancer patients

Cancer undercuts ability of normal cells to consume glucose, finds study

Cancer undercuts ability of normal cells to consume glucose, finds study

Researchers design new combination therapy for reducing NSCLC cell growth

Researchers design new combination therapy for reducing NSCLC cell growth

Loyola announces plans to produce CAR-T cells for treating cancer

Loyola announces plans to produce CAR-T cells for treating cancer

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

New discovery links proteins that control DNA packaging and cancer development

New discovery links proteins that control DNA packaging and cancer development

UCI researchers receive $3.4 million grant to study new class of cancer killing immunotherapeutics

UCI researchers receive $3.4 million grant to study new class of cancer killing immunotherapeutics

CytoSen receives favorable response from FDA to its pre-IND meeting package for CSTD002-NK

CytoSen receives favorable response from FDA to its pre-IND meeting package for CSTD002-NK

Lower clinical trial enrollment associated with relapse risk in AYA leukemia patients

Lower clinical trial enrollment associated with relapse risk in AYA leukemia patients

Rutgers study uncovers new mechanism linked to Alzheimer's and traumatic brain injury

Rutgers study uncovers new mechanism linked to Alzheimer's and traumatic brain injury

New approach for bone marrow transplant could make it safer and more effective for patients

New approach for bone marrow transplant could make it safer and more effective for patients

Research shows possibility to postpone cumbersome treatment for low-risk MDS patients

Research shows possibility to postpone cumbersome treatment for low-risk MDS patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.